AI takes on radiologists in prostate cancer detection trial
NCT ID NCT07647445
First seen Jun 16, 2026
Summary
This study compares an AI algorithm to radiologists in reading prostate MRI scans to detect clinically significant prostate cancer. About 500 men with suspected prostate cancer will have their MRI read by both AI and a radiologist, and results will be compared. If the AI performs just as well, it could help address the global shortage of radiologists.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI algorithm (Lucida Pi) for interpreting prostate MRI scans
What this could lead to
If successful, this could show that AI can reliably detect prostate cancer on MRI, helping to speed up diagnosis and reduce the workload on radiologists.
What could go wrong
This is an early-stage trial with 500 participants, and AI may miss some cancers or flag too many false alarms. It is not yet proven in real-world settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.